Rheumatoid arthritis in Latin America. Important challenges to be solved

Vargas, Rubén Burgos; Cardiel, Mario H.

doi:10.1007/s10067-015-3048-1

Cited by 15 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current challenges for the treatment of RA in Brazil, and other Latin American countries, include increasing access to prompt diagnosis, treatment by rheumatologists, and the availability of appropriate therapy. [ 3 , 45 , 46 ] Despite the availability of bDMARDs in Brazil, evidence suggests that few patients (<10% of those with moderate to severe RA) are prescribed these treatments. [ 47 ] This may be a consequence of poor access to treatment and attitudinal factors (e.g., fear of needles).…”

Section: Discussionmentioning

confidence: 99%

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis

Lomonte¹,

Radominski

Marcolino

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis

Lomonte¹,

Radominski

Marcolino

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…4,5 Based on epidemiological data, RA is a common disease, and late diagnosis is associated with structural damage and functional consequences. 6 Moreover, the mortality rate of patients with RA is still higher than in the general population. 7 Several comorbidities have also been reported in patients with RA, including depression, 8 asthma, cardiovascular events, and malignancies.…”

Section: Introductionmentioning

confidence: 99%

“…10 Despite these developments, the diagnosis of RA is delayed in many areas of the world, and patients remain undertreated, resulting in a great negative humanistic and socioeconomic impact. 6,11 Briefly, based on the Global Burden of Disease (GBD) 2017 study, the region of North Africa and Middle East (NAME) (12.8%) was among the top regions for statistically significant increasing trends in agestandardized incidence rates of RA. 12 Moreover, the NAME region has a wide variety of ethnicities, cultures, and lifestyles, which may affect the RA burden.…”

Section: Introductionmentioning

confidence: 99%

“…Based on epidemiological data, RA is a common disease, and late diagnosis is associated with structural damage and functional consequences 6 . Moreover, the mortality rate of patients with RA is still higher than in the general population 7 .…”

Section: Introductionmentioning

confidence: 99%

“…Advances in diagnostic tools and the availability of new therapeutic options have been of utmost importance for improving patient outcomes 10 . Despite these developments, the diagnosis of RA is delayed in many areas of the world, and patients remain undertreated, resulting in a great negative humanistic and socioeconomic impact 6,11 . Briefly, based on the Global Burden of Disease (GBD) 2017 study, the region of North Africa and Middle East (NAME) (12.8%) was among the top regions for statistically significant increasing trends in age‐standardized incidence rates of RA 12 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The burden of rheumatoid arthritis and low back pain in North Africa and Middle East from 1990 to 2019: Results from the Global Burden of Disease Study 2019

Sanjari,

Noorali,

Behnoush

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

BackgroundRheumatoid arthritis (RA) and low back pain (LBP) are among the most prevalent musculoskeletal disorders (MSDs). The need for investigation of regional and local patterns of these two MSDs seems inevitable for better policy‐making. The current study presents updated results of the Global Burden of Disease (GBD) Study 2019 and reports the burden of RA and LBP in North Africa and Middle East (NAME) countries from 1990 to 2019.MethodsIncidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), disability‐adjusted life‐years (DALYs), and risk factors, including high body mass index, occupational ergonomic factors, and smoking, were extracted based on the GBD 2019 data.ResultsThe age‐standardized prevalence and mortality of RA were 120.6 (95% uncertainty interval [95% UI] 107.0–135.7) and 0.1 (95% UI 0.1–0.2) per 100 000 population in 2019 with 28.3% (95% UI 25.5%–30.9%) increase and 7.5% (95% UI −37.5% to 32.5%) decrease since 1990, respectively. Turkey had the highest age‐standardized incidence, prevalence, and DALYs of RA in 2019. All RA burden measures were higher for women; however, the incidence was almost the same at ages greater than 65 years. The age‐standardized prevalence and DALYs of LBP were 7668.2 (95% UI 6798.0–8636.3) and 862 (95% UI 605.5–1153.3) in 2019, which had decreased by 5.8% (95% UI −7.4% to −4.3%) and 6.0% (95% UI −7.7% to −4.2%) since 1990, respectively. Moreover, although Turkey had the highest incidence and prevalence in 1990, Iran was at the top in 2019. The regional age‐standardized DALY rates due to RA and LBP attributed to smoking were 1.7 (95% UI 0.5–3.2) and 139.4 (95% UI 87.3–198.8) in 2019, respectively, which had decreased 2.2% (95% UI −19.2% to 13.7%) and 15.4% (95% UI −19.4% to −10.5%) since 1990, respectively.ConclusionRA still imposes a significant burden in the NAME region as the burden measures have increased from 1990 to 2019. On the other hand, regarding LBP, a decreasing pattern was observed. Differences among the countries and between ages and genders can have implications, and the results of this study may be helpful for policy‐makers in the NAME countries.

show abstract

Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal

Santos-Moreno¹,

Caballero-Uribe

Massardo³

et al. 2017

Clin Rheumatol

View full text Add to dashboard Cite

The implementation of excellence centers in specific diseases has been gaining recognition in the field of health; specifically in rheumatoid arthritis, where the prognosis of the disease is related to an early diagnosis and a timely intervention, it is necessary that the provision of health services is developed in an environment of quality, opportunity, and safety with the highest standards of care. A methodology that allows this implementation in such a way that is achievable by the most of the care centers is a priority to achieve a better attention to populations with this disease. In this paper, we propose a systematic and progressive methodology that will help all the institutions to develop successful models without faltering in the process. The expected impact on public health is defined by a better effective coverage of high-quality treatments, obtaining better health outcomes with safety and accessibility that reduces the budgetary impact for the health systems of our countries.

show abstract

Rheumatoid arthritis in Latin America. Important challenges to be solved

Cited by 15 publications

References 11 publications

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis

The burden of rheumatoid arthritis and low back pain in North Africa and Middle East from 1990 to 2019: Results from the Global Burden of Disease Study 2019

Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal

Contact Info

Product

Resources

About